Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Piccart, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piccart, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S89-S94, 2001
© 2001 European Society for Medical Oncology

Symposium Article

Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe

M. J. Piccart

Institut Jules Bordet Brussels, Belgium

Correspondence to: M. J. Piccart, MD, PhD Institut Jules Bordet Centre des Tumeurs de L'ULB Chemotherapy Department Rue Heger-Bordet 1 1000 Brussels Belgium E-mail: martine.piccart{at}bordet.be

The human epidermal growth factor receptor-2 (HER2) is overexpressed/amplified in 20%–30% of human breast tumors and is a marker for a poor prognosis. For these reasons, HER2 has been selected as a therapeutic target for breast cancer treatment. Oncologists can no longer ignore the importance of HER2 status for treatment algorithms in breast cancer. In light of the consequences of HER2 status on treatment selection, further research is warranted to refine and standardize HER2 testing in order to minimize false-negative results and optimize selection of treatment pathways. The anti-HER2 monoclonal antibody (MAb) trastuzumab (Herceptin) has proven valuable in treating HER2-positive, advanced-disease patients, and the availability of this novel biologic agent has important implications for clinical practice. This review describes a set of guidelines based on the current options for treatment of breast cancer. Two important factors have been taken into account in compiling these recommendations: (1) the lack of level I evidence to convincingly demonstrate the value of HER2 as a predictive marker for resistance or sensitivity to chemo- and hormonal therapy, and (2) the recently published pivotal phase II and III trial data proving the efficacy of trastuzumab as a single agent and in combination with chemotherapy in HER2-positive metastatic breast cancer.

anti-HER2 monoclonal antibody, HER2, Herceptin, predictive marker, prognostic marker, trastuzumab, treatment guidelines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 AM J HOSP PALLIAT CAREHome page
R. L. Barros Costa
Review Article: Targeted Therapy: Comprehensive Review
American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Biswal, B. Srinivasan, P. Dutta, P. Ranjan, K. Vaiphei, R. S. Singh, and S. S. Thingnam
Acromegaly Caused by Ectopic Growth Hormone: A Rare Manifestation of a Bronchial Carcinoid
Ann. Thorac. Surg., January 1, 2008; 85(1): 330 - 332.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51.
[Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
J. Pinto-de-Sousa, L. David, R. Almeida, D. Leitao, J. R. Preto, M. Seixas, and A. Pimenta
c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma
International Journal of Surgical Pathology, October 1, 2002; 10(4): 247 - 256.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
A. Rosner, K. Miyoshi, E. Landesman-Bollag, X. Xu, D. C. Seldin, A. R. Moser, C. L. MacLeod, G. Shyamala, A. E. Gillgrass, and R. D. Cardiff
Pathway Pathology : Histological Differences Between ErbB/Ras and Wnt Pathway Transgenic Mammary Tumors
Am. J. Pathol., September 1, 2002; 161(3): 1087 - 1097.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.